
|Videos|May 3, 2022
Aerie Pharmaceuticals continues their work in dry eye and glaucoma markets
Author(s)Kassi Filkins
Michelle Senchyna, PhD, VP Clinical Development and Medical Affairs for Aerie Pharmaceuticals, gives a company update on the various clinical trials in the pipeline.
Advertisement
Aerie Pharmaceuticals has multiple clinical trials in the pipeline for dry eye and glaucoma.
Michelle Senchyna, PhD, VP Clinical Development and Medical Affairs for Aerie Pharmaceuticals, shares a brief update on those.
Key pipeline highlights:
- After a successful phase 2, AR-15512 (0.003%), Aerie's novel dry eye product candidate, advances to phase 3 later this quarter.
- In late March, a phase 4 program kicked off with Aerie's product Rocklatan, Aerie's FDA-approved once-daily eye drop for the treatment of glaucoma. The phase 4 study is seeking to show data to demonstrate that it is the most powerful one drop, once a day formulation for the treatment of glaucoma.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Sharper vision starts here
2
Oculis to launch PIONEER trials for privosegtor in acute optic neuritis and NAION
3
iOpeners: Zubair Ansari, MD, shares his global health journey with Nicole Bajic, MD
4
Study finds retinal progenitor cell injections improve outcomes in rat model of diabetic retinopathy
5